Lost Money on Teva Pharmaceutical Industries Limited(TEVA)? You May Have Been Affected by Fraud – Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Teva Pharmaceutical Industries Limited ("Teva Pharmaceutical Industries Limited") (NYSE:TEVA) concerning possible violations of federal securities laws. On July 31, 2025, Teva published a press release reporting the Company’s second quarter 2025 financial […]

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

(NASDAQ:QNTM),(CNSX:QNTM.CN),(Boerse Frankfurt – Freiverkehr:0K91),(CNSX:QNTM), TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company“), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has received the clinical

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS) GlobeNewswire August 05, 2025 TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company“), a biopharmaceutical

Levi & Korsinsky Notifies Fiserv, Inc. (FI) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / If you suffered a loss on your Fiserv, Inc. (NYSE:FI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fiserv-inc-lawsuit-submission-form?prid=159751&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

ATTENTION Whirlpool Corporation Investors: You May Have Been Affected by Fraud – Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Whirlpool Corporation ("Whirlpool Corporation") (NYSE:WHR) concerning possible violations of federal securities laws. On July 29, 2025, Whirlpool issued a press release announcing positive second quarter results, featuring "sequential net sales growth across

SMX (Security Matters) Secures $11M in Growth Capital, Pushing 2025 Total Up To $20M

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / SMX (Security Matters) PLC (NASDAQ:SMX), a company revolutionizing supply chain transparency through technology that connects physical goods to secure digital records, today announced in a 6-K filing the signing of a Securities Purchase Agreement with institutional investors for up to $11 million in convertible

Fomento Econmico Mexicano, S.A.B. de C.V. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations – FMX

NEW YORK, NY / ACCESS Newswire / August 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fomento Econmico Mexicano, S.A.B. de C.V. ("Fomento Econmico Mexicano, S.A.B. de C.V.") (NYSE:FMX) concerning possible violations of federal securities laws. On July 28, 2025, Fomento issued a press release announcing their second

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

(NASDAQ:NVCT), NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminent Strengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025

StoneX Completes Acquisition of The Benchmark Company to Expand Investment Banking Capabilities

(NASDAQ:SNEX), NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) — StoneX Group Inc. (NASDAQ: SNEX), a global financial services firm connecting clients to the markets across asset classes and geographies, today announced the successful completion of its acquisition of The Benchmark Company, LLC (“Benchmark”), a leading provider of investment banking, equity research, and institutional sales and

Scroll to Top